Status:
UNKNOWN
Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma
Lead Sponsor:
University of Bologna
Conditions:
Diffuse Large B Cell Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
In Europe diffuse large B-cell lymphoma (DLBCL) is a rare disease whereas in Italy it is not. Approximately 40% of DLBCL patients has refractory disease or will relapse after initial response. In onco...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Patients affected by histologically confirmed diffuse large B-cell lymphoma
- Patients amenable for therapy with RCHOP (RCHOP is the standard first line therapy for DLBCL and it scheduled regardless of participation in present study).
- Patients must provide written informed consent.
Exclusion
- Concomitant second malignancy, other than lymphoma.
- Previous anti-lymphoma therapy.
- Pregnancy or breastfeeding.
- Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results.
Key Trial Info
Start Date :
April 2 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 20 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03797170
Start Date
April 2 2019
End Date
December 20 2023
Last Update
February 8 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)
Meldola, FC, Italy
2
Institute Of Hematology "Seràgnoli"
Bologna, Italy, 40138